Filter
420
Text search:
Booster
Featured
36
87
Language
Document type
182
99
54
24
18
18
8
7
4
2
2
2
Countries / Regions
27
20
11
11
8
8
7
7
7
7
6
6
6
6
5
5
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
150
62
23
19
10
4
2
Toolboxes
87
23
18
17
17
13
13
12
10
9
8
5
5
5
5
4
4
3
2
2
2
1
Disease outbreak news, 21 November 2019
Ce plan stratégique 2013- 2017 s’inscrit dans la continuité du précédent et a pour but de contribuer à la réduction de la charge de la tuberculose au Sénégal d’ici 2015 conformément aux Objectifs du Millénaire (OMD 6 Cible 8) et aux cibles du partenariat Halte à la tuberculose.
Les i
...
Report of the WHO Technical Advisory Group | 12 August 2016 | Geneva, Switzerland
Immunization in the context of COVID-19 pandemic
recommended
Immunizations are an essential health service that protect susceptible individuals from vaccine-preventable diseases (VPD).2 By providing timely immunizations, individuals and communities remain protected and the likelihood of a VPD outbreak decreases
This publication is available in Arabic, Chines
...
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir
...
Science . 2020 Sep 11;369(6509):1309-1312. doi: 10.1126/science.abe2803. Epub 2020 Sep 3.
The Fair Priority Model offers a practical way to fulfill pledges to distribute vaccines fairly and equitably
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
The objectives of pertussis surveillance are to:hmonitor disease burden and the impact of the pertussis vaccination programme, with a special focus on understanding the morbidity and mortality in children < 5 years of agehgenerate data to inform vaccine schedule and delivery strategy decisions to optimize the impact of
...
Available in English, French, Chinese, Arabic, Russian
8 February 2021
1 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 Infection Prevention and Control Sameeksha (Hindi; review) compiles recent key IPC resources on COVID from scientific journals, WHO guidelines, Ministry of Health and Family Welfare /Government of India guidelines, and trainings and IPC resources. The intended target audience for this inclu
...
Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran)
recommended
4 August 2021. Currently, Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) is the only COVID-19 vaccine that should be stored and transported at -60ºC to -86ºC ultra-low temperature (ULT) conditions. Prior to use the vaccine can be transferred to -20ºC freezer or +2-8ºC refrigerator at
...
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.
5 April 2022, Addendum. This policy brief confirms WHO guidance and policy on injection safety in the context of the extraordinary increase in global injections resulting from COVID-19 immunization campaigns. It also calls attention to information on specialized syringes for COVID-19 vaccines and br
...
This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian
...
New funding requirements: CHF 2.8 billion IFRC-wide of which CHF 670 million is channelled through the IFRC Emergency Appeal in support of National Societies
